Covid-19

COVID-19

UK study to test Pfizer’s Covid-19 pill in hospitalised patients

UK study to test Pfizer’s Covid-19 pill in hospitalised patients
A pharmacist displays a case of Paxlovid, a Covid-19 treatment pill developed by Pfizer Inc., at a drugstore in Seoul, South Korea, 21 February 2022. EPA-EFE/YONHAP SOUTH KOREA OUT
By Reuters
28 Mar 2022
0

March 28 (Reuters) - A British trial will investigate U.S. drugmaker Pfizer's PFE.N oral Covid-19 pill as a potential treatment for patients hospitalised with the illness, scientists said on Monday, as global coronavirus cases are surging once again.

The world’s largest randomised study of potential medicines for Covid-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain. It has already been approved in the country for the early-stage treatment of coronavirus infections.

“Paxlovid is a promising oral antiviral drug but we don’t know if it can improve survival of patients with severe Covid-19,” said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial.

Scientists said they aim to mainly find whether Paxlovid reduces the risk of death among patients admitted to hospitals with Covid-19.

The study, led by the University of Oxford, will also probe whether the treatment shortens the length of hospital stay or reduces the need for a mechanical ventilator, they added.

The Pfizer treatment is part of a class of drugs called protease inhibitors, currently used to treat HIV, hepatitis C and other viruses, and works by stopping the virus from replicating.

(Reporting by Shanima A in Bengaluru; Editing by Amy Caren Daniel)

Gallery

"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"

Investigations

News & Analysis

Features

Newsletters

Community

DM168

Daily Maverick © All rights reserved

Please peer review 3 community comments before your comment can be posted

[%% img-description %%]

The Spy Bill: An autocratic roadmap to State Capture 2.0

Join Heidi Swart in conversation with Anton Harber and Marianne Merten as they discuss a concerning push to pass a controversial “Spy Bill” into law by May 2024. Tues 5 Dec at 12pm, live, online and free of charge.

You’ll miss it when it’s gone...

It’s hard to imagine South Africa without journalism. Then again, it was unthinkable that we would be without electricity as much as we are. Daily Maverick is free to read. We don’t have a paywall because we believe that everyone, regardless of their financial status, should be able to access the news. Which gives our journalism a greater chance of broader impact on society.

If you agree that our work makes South Africa a better place (and want to see us keep doing it) then please consider joining Maverick Insider and supporting our journalism.

You choose the amount and you can cancel at any time.

JOIN THE CAUSE
Lightbulb

A South African Hero: You

There’s a 99.8% chance that this isn’t for you. Only 0.2% of our readers have responded to this call for action.

Those 0.2% of our readers are our hidden heroes, who are fuelling our work and impacting the lives of every South African in doing so. They’re the people who contribute to keep Daily Maverick free for all, including you.

The equation is quite simple: the more members we have, the more reporting and investigations we can do, and the greater the impact on the country.

Be part of that 0.2%. Be a Maverick. Be a Maverick Insider.

Support Daily Maverick→
Payment options